These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 4372111

  • 1. Xanthomatosis and hyperlipoproteinemia; a review.
    Polano MK.
    Dermatologica; 1974; 149(1):1-9. PubMed ID: 4372111
    [No Abstract] [Full Text] [Related]

  • 2. Bile acid metabolism in hyperlipoproteinaemia.
    Hellström K, Einarsson K.
    Clin Gastroenterol; 1977 Jan; 6(1):103-28. PubMed ID: 196796
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of hyperlipidemia.
    Levy RI, Morganroth J, Rifkind BM.
    N Engl J Med; 1974 Jun 06; 290(23):1295-301. PubMed ID: 4363888
    [No Abstract] [Full Text] [Related]

  • 4. [Hyperlipoproteinemia].
    Meinders AE.
    Ned Tijdschr Geneeskd; 1979 Mar 14; 123(15):617-28. PubMed ID: 219378
    [No Abstract] [Full Text] [Related]

  • 5. [Xanthomatosis as a symptom of hyperlipidemic metabolic disorders. Relationship of the morphological picture to the lipid of three patients].
    Rufli T, Stähelin H.
    Dermatologica; 1972 Mar 14; 144(5):270-82. PubMed ID: 4351630
    [No Abstract] [Full Text] [Related]

  • 6. [Familial hyperlipoproteinemia type III].
    Patsch JR, Patsch W, Sailer S, Braunsteiner H.
    Dtsch Med Wochenschr; 1976 Oct 29; 101(44):1612-9. PubMed ID: 185039
    [No Abstract] [Full Text] [Related]

  • 7. Dietary and drug treatment of primary hyperlipoproteinemia.
    Ann Intern Med; 1972 Aug 29; 77(2):267-94. PubMed ID: 4345081
    [No Abstract] [Full Text] [Related]

  • 8. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
    Patsch JR, Yeshurun D, Jackson RL, Gotto AM.
    Am J Med; 1977 Dec 29; 63(6):1001-9. PubMed ID: 204188
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of hypolipidemic drugs on serum lipoproteins.
    Carlson LA, Olsson AG.
    Prog Biochem Pharmacol; 1979 Dec 29; 15():238-57. PubMed ID: 224397
    [No Abstract] [Full Text] [Related]

  • 17. Pediatric familial type II hyperlipoproteinemia: therapy with diet and cholestyramine resin.
    Glueck CJ, Fallat R, Tsang R.
    Pediatrics; 1973 Nov 29; 52(5):669-79. PubMed ID: 4355362
    [No Abstract] [Full Text] [Related]

  • 18. [The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clofibrate and m-inositol nicotinate therapy].
    Schwartzkopff W, Zschiedrich M.
    Verh Dtsch Ges Inn Med; 1976 Nov 29; 82 Pt 1():825-9. PubMed ID: 196436
    [No Abstract] [Full Text] [Related]

  • 19. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L, Olsson AG, Rössner S, Carlson LA.
    Postgrad Med J; 1975 Nov 29; 51(8):76-81. PubMed ID: 176639
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.